Drug Profile


Alternative Names: R 70380

Latest Information Update: 11 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen L.P.
  • Developer Janssen L.P.; Nonindustrial source
  • Class Antiplatelets; Piperazines
  • Mechanism of Action Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 11 Jun 2000 Discontinued-Clinical for Ischaemic heart disorders in Belgium (Unknown route)
  • 11 Jun 2000 Discontinued-Clinical for Ischaemic heart disorders in Netherlands (Unknown route)
  • 11 Jun 2000 Discontinued-Preclinical for Ischaemic heart disorders in Norway (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top